Pharmaceuticals

Prostate Cancer Drugs Market Research: Growth Projections and Trends 2030

February 18, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the prostate cancer drugs market from 2026–2035 with trusted insights from The Business Research Company

What level of growth is expected in the Prostate Cancer Drugs Market between 2026 and 2030?

The prostate cancer drugs market has experienced robust growth in recent years. It is anticipated to expand from $19.51 billion in 2025 to $20.54 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 5.3%. The historical increase can be ascribed to an aging male population, augmented prostate cancer screening efforts, widespread embrace of hormone therapy, the proliferation of oncology clinics, and heightened cancer awareness.

The prostate cancer drugs market is projected for robust expansion in the coming years, with its valuation anticipated to reach $26.15 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.2%. This anticipated growth is driven by factors such as the development of targeted and immunotherapy drugs, an increase in advanced prostate cancer cases, greater individualization of treatment, broader healthcare accessibility, and increased expenditure on oncology. Key developments during this period are expected to include the rising application of hormonal therapy in initial treatments, wider acceptance of specific prostate cancer drugs, enhanced attention on castration-resistant prostate cancer, an increase in combination therapy strategies, and more prostate cancer care provided in hospital settings.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2592&type=smp

Which Drivers Are Expected To Impact The Prostate Cancer Drugs Market During The Forecast Period?

The expanding demographic of elderly men is anticipated to boost the prostate cancer drugs market in the coming period. This demographic, comprising males aged 65 and above, generally encounters a higher incidence of age-associated health issues, necessitating particular medical care. The global increase in this older male group stems from better access to healthcare, reduced death rates, and extended longevity worldwide. The growing elderly male demographic contributes to the demand for prostate cancer drugs by increasing the patient pool who need hormonal therapies, immunotherapies, chemotherapy, and targeted medicines to manage their disease and enhance survival. As an illustration, the World Health Organization, an international public health body located in Switzerland, reported in February 2025 that the global life expectancy at birth reached 73.3 years in 2024, with the worldwide population aged 60 and above expected to climb from 1.1 billion in 2023 to 1.4 billion by 2030. Consequently, the expanding geriatric male population is a key factor fueling the growth of the prostate cancer market.

Which Segments Are Driving Activity In The Prostate Cancer Drugs Market?

The prostate cancer drugs market covered in this report is segmented –

1) By Type: Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer

2) By Therapy: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy

3) By End User: Hospitals, Clinics, Other End-Users

Subsegments:

1) By Hormone Sensitive Prostate Cancer: Early-Stage Prostate Cancer, Locally Advanced Prostate Cancer, Metastatic Prostate Cancer

2) By Hormone Refractory Prostate Cancer: Castration-Resistant Prostate Cancer (CRPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Which Trends Are Expected To Influence The Prostate Cancer Drugs Market In The Upcoming Years?

Major companies operating within the prostate cancer drugs market are focusing their efforts on introducing new products and securing their approval from federal agencies, aiming to maximize their revenue in the sector. The process of developing and getting drugs approved is extensive and intricate, making it crucial for drug sponsors to comprehend the regulatory controls and marketing pathways necessary to ensure a reasonable degree of safety and effectiveness. For instance, in June 2023, AstraZeneca PLC, a UK-based pharmaceutical company, and Merck & Co. Inc., a US-based pharmaceutical company, revealed that the United States Food and Drug Administration’s (USFDA), a US-based federal agency of the Department of Health and Human Services, had approved LYNPARZA (olaparib) Plus Abiraterone and Prednisone or Prednisolone for the treatment of adult patients with BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). An exploratory subgroup analysis from the Phase 3 PROpel trial, which formed the basis for this approval, indicated that LYNPARZAplus abi/pred significantly improved both radiographic progression-free survival (rPFS) and overall survival (OS) when compared to abi/pred alone in patients with BRCAm mCRPC.

Which Leading Companies Dominate The Prostate Cancer Drugs Market Share?

Major companies operating in the prostate cancer drugs market are Astellas Pharma Inc., AstraZeneca PLC, Johnson & Johnson, Sanofi S.A., Bayer AG, Abbott Laboratories, Pfizer Inc., Novartis International AG, F. Hoffmann-La Roche Ltd., Tolmar Inc., AbbVie Inc., Siemens Healthineers AG, Genomic Health Inc., OPKO Health Inc., Siemens Healthcare GmbH, MDxHealth SA, Myriad Genetics Inc., Janssen Biotech Inc., Clovis Oncology Inc., Merck Sharp & Dohme Corp., Dendreon Corporation, Ferring Pharmaceuticals Inc., Ipsen Biopharmaceuticals Inc., Merck & Co. Inc., Eli Lilly and Company Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novartis AG, Amgen Inc., Regeneron Pharmaceuticals Inc., Exelixis Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

How Does The Prostate Cancer Drugs Market Perform Across Major Global Regions?

North America was the largest region in the prostate cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the prostate cancer drugs market during the forecast period. The regions covered in the prostate cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Prostate Cancer Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=2592&type=smp

Browse Through More Reports Similar to the Global Prostate Cancer Drugs Market 2026, By The Business Research Company

Prostate Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/prostate-cancer-drugs-global-market-report

Metastatic Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-cancer-drugs-global-market-report

Bladder Cancer Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795